Small Molecule

Valeant and Salix Agree on Amended Merger Terms

Mar 16, 2015

Valeant Pharmaceuticals and Salix Pharmaceuticals announced that they have amended their Agreement and Plan of Merger, dated February 20, 2015. Pursuant to the amendment, Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158.00 per share to $173.00 per share in cash, or a total enterprise value of approximately $15.8 billion.

As previously announced, Valeant expects to close the transaction on April 1, 2015. If all of the conditions to the tender offer have not been satisfied by April 8, 2015, the offer price will drop back to $158.00 per share.

Read the Valeant press release